Richard E. Champlin

76.4k total citations · 11 hit papers
1.1k papers, 45.3k citations indexed

About

Richard E. Champlin is a scholar working on Hematology, Oncology and Immunology. According to data from OpenAlex, Richard E. Champlin has authored 1.1k papers receiving a total of 45.3k indexed citations (citations by other indexed papers that have themselves been cited), including 760 papers in Hematology, 353 papers in Oncology and 227 papers in Immunology. Recurrent topics in Richard E. Champlin's work include Hematopoietic Stem Cell Transplantation (489 papers), Acute Myeloid Leukemia Research (242 papers) and Acute Lymphoblastic Leukemia research (162 papers). Richard E. Champlin is often cited by papers focused on Hematopoietic Stem Cell Transplantation (489 papers), Acute Myeloid Leukemia Research (242 papers) and Acute Lymphoblastic Leukemia research (162 papers). Richard E. Champlin collaborates with scholars based in United States, United Kingdom and Italy. Richard E. Champlin's co-authors include Sergio Giralt, Issa F. Khouri, Börje S. Andersson, Paolo Anderlini, Robert Peter Gale, Elizabeth J. Shpall, Marcos de Lima, Gabriela Rondón, Chitra Hosing and Hagop M. Kantarjian and has published in prestigious journals such as Science, New England Journal of Medicine and Proceedings of the National Academy of Sciences.

In The Last Decade

Richard E. Champlin

1.1k papers receiving 44.2k citations

Hit Papers

Donor leukocyte infusions in 140 patients with relapsed m... 1988 2026 2000 2013 1997 1997 2004 2002 1998 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.
    1997 993 citations Sergio Giralt, Richard E. Champlin et al. profile →
  2. Engraftment of Allogeneic Hematopoietic Progenitor Cells With Purine Analog-Containing Chemotherapy: Harnessing Graft-Versus-Leukemia Without Myeloablative Therapy
    1997 909 citations Sergio Giralt, Gabriela Rondón et al. Blood profile →
  3. Outcomes after Transplantation of Cord Blood or Bone Marrow from Unrelated Donors in Adults with Leukemia
    2004 783 citations Mary Eapen, Richard E. Champlin et al. profile →
  4. Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors.
    2002 768 citations Richard E. Champlin et al. profile →
  5. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies.
    1998 738 citations Issa F. Khouri, Paolo Anderlini et al. profile →
  6. Hepatocytes and Epithelial Cells of Donor Origin in Recipients of Peripheral-Blood Stem Cells
    2002 611 citations Martin Körbling, Gabriela Rondón et al. profile →
  7. Diagnosis of chronic myeloid and acute lymphocytic leukemias by detection of leukemia-specific mRNA sequences amplified in vitro.
    1988 603 citations Richard E. Champlin et al. Proceedings of the National Academy of Sciences profile →
  8. Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study
    2007 557 citations Mary Eapen, Mei-Jie Zhang et al. profile →
  9. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia
    2000 531 citations Jeffrey J. Molldrem, Hagop M. Kantarjian et al. profile →
  10. Membrane-Bound IL-21 Promotes Sustained Ex Vivo Proliferation of Human Natural Killer Cells
    2012 489 citations Cecele J. Denman, V. V. Senyukov et al. PLoS ONE profile →
  11. Zygomycosis in a Tertiary‐Care Cancer Center in the Era of Aspergillus‐ Active Antifungal Therapy: A Case‐Control Observational Study of 27 Recent Cases
    2005 489 citations Hagop M. Kantarjian, Richard E. Champlin et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Richard E. Champlin United States 113 27.2k 14.9k 12.6k 8.4k 7.1k 1.1k 45.3k
Arnon Nagler Israel 88 21.6k 0.8× 12.5k 0.8× 12.6k 1.0× 6.0k 0.7× 5.4k 0.8× 1.1k 39.3k
Daniel J. Weisdorf United States 96 24.2k 0.9× 11.4k 0.8× 13.3k 1.1× 5.1k 0.6× 6.3k 0.9× 732 38.4k
Rainer Storb United States 126 48.8k 1.8× 15.7k 1.0× 19.1k 1.5× 11.9k 1.4× 10.2k 1.4× 1.1k 67.2k
Stephen J. Forman United States 100 12.3k 0.5× 16.3k 1.1× 9.1k 0.7× 4.5k 0.5× 4.8k 0.7× 861 36.2k
Sergio Giralt United States 86 21.4k 0.8× 10.0k 0.7× 7.0k 0.6× 5.0k 0.6× 4.9k 0.7× 856 30.2k
Frederick R. Appelbaum United States 105 30.9k 1.1× 10.1k 0.7× 7.0k 0.6× 8.9k 1.1× 10.6k 1.5× 595 42.6k
Paul J. Martin United States 98 20.5k 0.8× 6.9k 0.5× 12.4k 1.0× 4.5k 0.5× 4.9k 0.7× 568 34.2k
Gèrard Socié France 91 18.7k 0.7× 7.4k 0.5× 9.2k 0.7× 4.8k 0.6× 4.9k 0.7× 701 30.2k
Franco Locatelli Italy 88 12.5k 0.5× 8.4k 0.6× 9.9k 0.8× 8.1k 1.0× 3.7k 0.5× 1.0k 33.0k
Jerome Ritz United States 103 12.9k 0.5× 10.1k 0.7× 19.0k 1.5× 4.8k 0.6× 3.1k 0.4× 610 36.4k

Countries citing papers authored by Richard E. Champlin

Since Specialization
Citations

This map shows the geographic impact of Richard E. Champlin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard E. Champlin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard E. Champlin more than expected).

Fields of papers citing papers by Richard E. Champlin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard E. Champlin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard E. Champlin. The network helps show where Richard E. Champlin may publish in the future.

Co-authorship network of co-authors of Richard E. Champlin

This figure shows the co-authorship network connecting the top 25 collaborators of Richard E. Champlin. A scholar is included among the top collaborators of Richard E. Champlin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard E. Champlin. Richard E. Champlin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Nieto, Yago, Jeremy Ramdial, Benigno C. Valdez, et al.. (2025). Enhancement of High-Dose Chemotherapy and Autologous SCT with the PARP Inhibitor Olaparib for Refractory Lymphoma. Clinical Cancer Research. 31(6). 975–982. 1 indexed citations
2.
Joseph, Jacinth, Samer A. Srour, Denái R. Milton, et al.. (2023). Transplantation Outcomes of Myelofibrosis with Busulfan and Fludarabine Myeloablative Conditioning. Transplantation and Cellular Therapy. 29(12). 770.e1–770.e6. 3 indexed citations
3.
Saliba, Rima M., Christopher G. Kanakry, Shahinaz M. Gadalla, et al.. (2023). Effect of donor age in patients with acute myeloid leukemia undergoing haploidentical hematopoietic cell transplantation vary by conditioning intensity and recipient age. American Journal of Hematology. 99(1). 38–47. 7 indexed citations
4.
Mehta, Rohtesh S., Jeremy Ramdial, David Marín, et al.. (2023). Impact of Donor Age in Haploidentical-Post-Transplantation Cyclophosphamide versus Matched Unrelated Donor Post-Transplantation Cyclophosphamide Hematopoietic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia. Transplantation and Cellular Therapy. 29(6). 377.e1–377.e7. 14 indexed citations
5.
Short, Nicholas J., Farhad Ravandi, Graciela M. Nogueras‐González, et al.. (2023). Impact of type of induction therapy on outcomes in older adults with AML after allogeneic stem cell transplantation. Blood Advances. 7(14). 3573–3581. 13 indexed citations
6.
Davies, Jeff, Lisa Brennan, John R. Wingard, et al.. (2018). Infusion of Alloanergized Donor Lymphocytes after CD34-selected Haploidentical Myeloablative Hematopoietic Stem Cell Transplantation. Clinical Cancer Research. 24(17). 4098–4109. 7 indexed citations
7.
8.
Ciurea, Stefan O., Jolie Schafer, Roland L. Bassett, et al.. (2017). Phase 1 clinical trial using mbIL21 ex vivo–expanded donor-derived NK cells after haploidentical transplantation. Blood. 130(16). 1857–1868. 250 indexed citations
9.
Hurton, Lenka V., Harjeet Singh, Amer Najjar, et al.. (2016). Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells. Proceedings of the National Academy of Sciences. 113(48). E7788–E7797. 341 indexed citations
10.
Caruso, Hillary G., Lenka V. Hurton, Amer Najjar, et al.. (2015). Tuning Sensitivity of CAR to EGFR Density Limits Recognition of Normal Tissue While Maintaining Potent Antitumor Activity. Cancer Research. 75(17). 3505–3518. 324 indexed citations
11.
Deniger, Drew C., Sourindra N. Maiti, Tiejuan Mi, et al.. (2014). Activating and Propagating Polyclonal Gamma Delta T Cells with Broad Specificity for Malignancies. Clinical Cancer Research. 20(22). 5708–5719. 104 indexed citations
12.
Denman, Cecele J., V. V. Senyukov, Srinivas S. Somanchi, et al.. (2012). Membrane-Bound IL-21 Promotes Sustained Ex Vivo Proliferation of Human Natural Killer Cells. PLoS ONE. 7(1). e30264–e30264. 489 indexed citations breakdown →
13.
Zhang, Minying, Sourindra N. Maiti, Chantale Bernatchez, et al.. (2012). A New Approach to Simultaneously Quantify Both TCR α- and β-Chain Diversity after Adoptive Immunotherapy. Clinical Cancer Research. 18(17). 4733–4742. 15 indexed citations
14.
Singh, Harjeet, Matthew J. Figliola, Margaret J. Dawson, et al.. (2011). Reprogramming CD19-Specific T Cells with IL-21 Signaling Can Improve Adoptive Immunotherapy of B-Lineage Malignancies. Cancer Research. 71(10). 3516–3527. 161 indexed citations
15.
Ciurea, Stefan O., Peter F. Thall, Xuemei Wang, et al.. (2011). Donor-specific anti-HLA Abs and graft failure in matched unrelated donor hematopoietic stem cell transplantation. Blood. 118(22). 5957–5964. 148 indexed citations
16.
17.
18.
Komanduri, Krishna V., Daniel R. Couriel, & Richard E. Champlin. (2006). Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation: Evolving Concepts and Novel Therapies Including Photopheresis. Biology of Blood and Marrow Transplantation. 12(1). 1–6. 13 indexed citations
19.
Hanrahan, Emer O., Kristine Broglio, Aman U. Buzdar, et al.. (2006). Randomized trial of high‐dose chemotherapy and autologous hematopoietic stem cell support for high‐risk primary breast carcinoma. Cancer. 106(11). 2327–2336. 20 indexed citations
20.
Champlin, Richard E., Issa F. Khouri, Paolo Anderlini, et al.. (2001). Nonmyeloablative preparative regimens for allogeneic hematopoietic transplantation. Bone Marrow Transplantation. 27(S2). S13–S22. 37 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Arnon Nagler Breakdown of academic impact, for papers by Daniel J. Weisdorf Breakdown of academic impact, for papers by Rainer Storb Breakdown of academic impact, for papers by Stephen J. Forman Breakdown of academic impact, for papers by Sergio Giralt Breakdown of academic impact, for papers by Frederick R. Appelbaum Breakdown of academic impact, for papers by Paul J. Martin Breakdown of academic impact, for papers by Gèrard Socié Breakdown of academic impact, for papers by Franco Locatelli Breakdown of academic impact, for papers by Jerome Ritz
Rankless by CCL
2026